uPAR / CD87 active protein

Recombinant Human uPAR Protein (His Tag)(Active)

Cat. Num. AAA22094

• Gene Names: PLAUR; CD87; UPAR; URKR; U-PAR
• Purity: > 98 % as determined by reducing SDS-PAGE.
• Synonyms: uPAR / CD87; Recombinant Human uPAR Protein (His Tag)(Active); Urokinase Plasminogen Activator Surface Receptor; U-PAR; uPAR; Monocyte activation antigen; Mo3; CD87; PLAUR; MO3; UPAR; uPAR / CD87 active protein

• Host: HEK293 Cells
• Purity/Purification: > 98 % as determined by reducing SDS-PAGE.
• Form/Format: Lyophilized from sterile PBS, pH 7.4, 5% Trehalose, 5% Mannitol, 0.01% Tween-80.
• Sequence Positions: Met 1-Arg 303

• Species: Human
• Tag: C-His
• Bio_activity: Measured by its binding ability in a functional ELISA . Immobilized human uPAR at 5 ug/ml (100 ul/well) can bind biotinylated human UPA with a linear ranger of 40-1000 ng/ml.
• Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method.
• Reconstitution: It is recommended that sterile water (800uL) be added to the vial to prepare a stock solution of 0.25mg/mL. Concentration is measured by UV-Vis.
• Preparation and Storage: Storage: Lyophilized proteins are stable for up to 12 months when stored at -20 to -80 degree C. Reconstituted protein solution can be stored at 4-8 degree C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 degree C for 3 months.; Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

SDS-PAGE

Related Product Information for uPAR / CD87 active protein

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinasetype plasminogen activator receptor - uPAR) expression has a potential role in the prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

NCBI and Uniprot Product Information

• NCBI GI #: 53829379
• NCBI GeneID: 5329
• NCBI Accession #: NP_001005376.1
• NCBI GenBank Nucleotide #: NM_001005376.2
• UniProt Accession #: Q03405-1; Q12876; Q15845; Q16887; Q6IB52; Q9BWT0; Q9NYC8; Q9UD69; Q9UEA6; Q9UM92; Q9UMV0; A8K409; Q03405
• Molecular Weight: Mol_Mass: 32.8 kDa; AP_Mol_Mass: 48 kDa
• NCBI Official Full Name: urokinase plasminogen activator surface receptor isoform 2
• NCBI Official Synonym Full Names: plasminogen activator, urokinase receptor
• NCBI Official Symbol: PLAUR
• NCBI Official Synonym Symbols: CD87; UPAR; URKR; U-PAR
• NCBI Protein Information: urokinase plasminogen activator surface receptor
• UniProt Protein Name: Urokinase plasminogen activator surface receptor
• UniProt Gene Name: PLAUR
• UniProt Synonym Gene Names: MO3; UPAR; U-PAR; uPAR